Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS0101, M7824, and NHS-IL12 in Advanced HPV Associated Malignancies
NCT04287868Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Nanoparticles, Immunomodulatory ADCs
- Countries
- 1
01
Overview
A Phase 2 trial of PDS0101, bintrafusp alfa, NHS-IL-12 in human papillomavirus-associated malignancy, sponsored by National Cancer Institute. Started Jun 2020; status: completed.
02
Drugs
PDS0101bintrafusp alfaNHS-IL-12
03
Conditions
human papillomavirus-associated malignancy
Beyond the preview
Go deeper on NCT04287868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287868.